Johnson & Johnson must pay US$8b over drug side effect: jury
[NEW YORK] A Pennsylvania jury ruled on Tuesday that US pharmaceutical giant Johnson & Johnson must pay US$8 billion in damages and interest for failing to warn that a psychiatric drug could cause breast growth in men.
Johnson & Johnson and its subsidiary Janssen Pharmaceuticals were blamed as plaintiff Nicholas Murray told the Philadelphia court that the drug Risperdal, prescribed to treat schizophrenia and bipolar disorder, had made him grow breasts.
The company challenged the ruling in a statement, calling the damages awarded "grossly disproportionate" with the initial award in the case of US$680,000.
"The company is confident (the ruling) will be overturned," the statement said, and "will be immediately moving to set aside this excessive and unfounded verdict."
In the statement, Johnson & Johnson accused the court of preventing their defence team from presenting "key evidence" on Risperdal labeling.
The company is facing a series of complaints in state courts for failing to properly warn of Risperdal's side effects, including in Pennsylvania, California and Missouri.
Risperdal, approved for the treatment of adults by the US Food and Drug Administration in 1993, brought in some US$737 million (S$1.02b) in sales in 2018.
AFP
KEYWORDS IN THIS ARTICLE
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Consumer & Healthcare
Nestle sales growth sputters on US slump, vitamin snags
Hermes Q1 sales jump 17% on strong China demand
Cordlife’s independent auditor to retire after issuing disclaimer of opinion on FY2023 financials
Cutting the cord?: Events leading up to Cordlife’s MOH suspension and arrests of its directors, ex-group CEO
Cordlife customers push for legal action
France's Casino supermarket chain to axe up to 3,200 jobs